Production approval for Finerenone

Release date: 2024-07-10 14:43:32     Recommended: 357

Finerenone is a non steroidal selective mineralocorticoid receptor antagonist that has been shown in preclinical studies to block harmful effects caused by excessive activation of mineralocorticoid receptors. In patients with diabetes, over activation of the mineralocorticoid receptor is believed to lead to the progression of chronic kidney disease and cardiovascular damage, which may be driven by factors such as metabolism, hemodynamics or inflammation and fibrosis.